Skip to Content

Micafungin Pregnancy and Breastfeeding Warnings

Micafungin is also known as: Mycamine

Micafungin Pregnancy Warnings

Animal studies have revealed evidence of embryotoxicity. Micafungin administered IV to pregnant rabbits on days 6 to 18 of gestation resulted in visceral abnormalities (including abnormal lobation of the lung, levocardia, retrocaval ureter, anomalous right subclavian artery, dilatation of the ureter) and increased abortion at doses (32 mg/kg) equal to about 4 times the recommended human dose (based on body surface area comparison). There are no controlled data in human pregnancy.

FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

FDA pregnancy category: C

Micafungin should be used during pregnancy only if the potential benefit outweighs the potential risk.

See references

Micafungin Breastfeeding Warnings

Caution is recommended.

Excretion into human milk: Unknown
Excretion into animal milk: Unknown

The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Mycamine (micafungin)." Fujisawa, Deerfield, IL.

References for breastfeeding information

  1. "Product Information. Mycamine (micafungin)." Fujisawa, Deerfield, IL.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide